Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 36.50 36.00 37.00 36.50 36.50 36.50 22,759 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -21.9 -9.8 - 128

Advanced Oncotherapy Share Discussion Threads

Showing 5326 to 5348 of 5475 messages
Chat Pages: 219  218  217  216  215  214  213  212  211  210  209  208  Older
DateSubjectAuthorDiscuss
11/10/2018
10:36
It would be nice if AVO came good but I still have reservations about the BoD.
daijavu
11/10/2018
08:26
This flurry of releases esp the paid for goetz "research" tip designed to prop up the sp, smells of a placing in the offing.
twirl
10/10/2018
17:49
That was certainly the start of a much needed upturn.
paul_98
10/10/2018
07:46
Flash note now published on AVO website also! hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/xzze87x
makeamillion1
10/10/2018
07:17
hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/xompdmr
makeamillion1
10/10/2018
07:09
hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/xompdmr The company is making very good progress! Excellent Technological Update today!
makeamillion1
05/10/2018
12:59
Still on track....STFC's Daresbury Laboratory gears up to test next generation of cancer treatment?Computer aided design image of the new facility.(Credit: STFC)In May, STFC's Daresbury Laboratory signed a major agreement with British company Advanced Oncotherapy, to build a mass assembly and testing centre for the world's next generation of proton therapy to treat cancer.The technology behind Advanced Oncotherapy's LIGHT system, span out of CERN, the home of the Large Hadron Collider, and is designed to reduce the cost and improve the performance of proton therapy to treat cancer and will be a significant milestone advancement in cancer therapy.Work is now progressing at Daresbury Laboratory to build and prepare the test facility ready for the installation and assembly of the full LIGHT system from later this year.STFC's Neil Bliss, who is managing the project said: "Things have been extremely busy, we're completing project milestones to a strict schedule to ensure that everything is coming together, on track for Advanced Oncotherapy's LIGHT system installation next month, ready for full-energy testing next year. The concrete shielding for the proton injector and RF test bunkers are in place. At the same time, the supporting steel work and the necessary electrical installations are well underway. This is just a snapshot of the design and planning activities taking place behind the scenes in preparation. We're thrilled that Daresbury Laboratory's expertise in particle accelerators and facility construction are contributing towards what will be a key milestone advancement in proton therapy."Read more: STFC's Daresbury Lab to test next generation of cancer treatment.Proton therapyProton therapy produces fewer side effects than conventional radiotherapy. It uses beams of protons to precisely target cancerous tumours while limiting damage to surrounding organs or tissue. Offering higher disease-free survival rates, proton therapy is most often used to treat brain tumours in young children whose organs and tissues are still developing, or cancers adjacent to critical part of the body (liver, lung, head and neck, prostate, breast).
rpctech66
30/9/2018
17:33
The technological advances far outweigh things here now. I expect gains.
paul_98
28/9/2018
18:06
I'm not. It is quite usual for the market not to notice, especially in the case of small companies like AVO who have no income and, as far as most people are concerned, no clear prospects. It takes people like us who have an exceptional interest in the company to notice. I've dipped my toe in again and I hope I don't regret it.
daijavu
28/9/2018
14:10
I am a little surprised by the small upward movement in the share price
paul_98
28/9/2018
07:18
Half Year Report published: hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/x8ne3ox Hopefully setting up for a good day!
makeamillion1
27/9/2018
16:26
Surprised it hasn't been a better day. After the next update in a few days, which surely must also be positive(?) then we should see more director buying, plus others. Certainly this is a milestone - proven treatment, albeit small scale, and still with long walk ahead. But should provide a huge boost for the "sales team". Definitely strongly pointing forward now.
justjill
27/9/2018
12:16
Yes, buys coming in!
marvin66
27/9/2018
12:05
I actually bought some today
daijavu
27/9/2018
12:04
There is a fair amount of buying today so perhaps the share price might move.
daijavu
27/9/2018
08:24
I read the update and so did Mr Market. Mr market has barely flickered an eyelid. Not yet. Give it a day or two.
daijavu
27/9/2018
08:18
Read the update and more to follow. Cheer up! This is superb.
paul_98
27/9/2018
08:10
boom? What boom?
daijavu
27/9/2018
07:50
As guessed boom!!!
paul_98
27/9/2018
07:20
ADVANCED ONCOTHERAPY PLC (“Advanced Oncotherapy” or the “Company”;) Technological update Key technological milestone completed on schedule LIGHT system now generating proton beams with energies required to treat superficial tumours Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, provides an update on the technological development of its LIGHT system. The Company announces that it has reached a key milestone in the development of its next-generation proton therapy technology, the LIGHT system. The first system under development at the Company’s testing facility at CERN, Geneva is now generating a proton beam with sufficient energy required for treating some superficial tumours. Superficial tumours include ocular tumours, parotid gland tumours, basal cell carcinoma, and some soft tissue sarcomas, to name a few. A specific type of basal cell carcinoma, known as periocular tumours, was modelled for the purpose of establishing the treatment plan based on the data and the proton acceleration reached with the LIGHT system. Periocular tumours are challenging to treat because of their proximity to the eye. Protons may offer an advantage for these patients by largely sparing the eyes and eye lenses from radiation dose. The resulting plan is available on the website of the company and ‑ based on the proton acceleration generated ‑ shows that: · The current LIGHT system comfortably covers the simulated clinical case, as well as some marginally deeper tumours · The healthy tissue ‑ such as the eye and the lens ‑ is dramatically spared from radiation dose with a steep decrease of the radiation levels directly next to the tumour site · The lens dose is well controlled and the radiation dose around the optic nerve is near zero The Treatment Planning Software (“TPS”) used in the LIGHT system has been developed by AVO’s partner, RaySearch AB and will be further tailored to include LIGHT system’s many advanced features for AVO’s proprietary use. The LIGHT system is designed to elicit significant advantages over existing proton therapy technology, such as a higher beam precision and targeting which results in a more conformal dose and greater adjustability at source. Furthermore, the accelerator varies the beam energy actively and therefore significantly reduces undesired secondary radiation seen in traditional proton therapy systems. This ‑ together with the modular design of the LIGHT system ‑ result in thinner radiation shielding next to the accelerator and a smaller foot-print. This makes the LIGHT systems easier and cheaper to operate and install in city-centre locations as compared to systems currently on the market. Taken altogether, these features make the LIGHT system the ideal tool for making proton therapy systems more widely available, with a technology expected to be capable of providing improved outcomes and reduced treatment related side effects. Having reached this milestone on schedule the development team are now focussed on the relatively low-execution risk activity of adding further accelerating modules with the objective of treating all indications suitable for proton therapy. A further technical update will be provided in the next few days. Commenting, Nicolas Sérandour, CEO of Advanced Oncotherapy, said: “We are delighted to have achieved this key milestone in the development of our first LIGHT system. I am also very proud of our team and thankful for their dedication in achieving this milestone. This announcement marks the shift from a complex ‑ albeit well-proven ‑ scientific and physics reality into a medical application with tangible and direct implications for patients. This very important step supports the confidence we have in delivering our plan and being in a position to offer a system that delivers a better outcome for patients whilst generating more value for the operators.”
makeamillion1
27/9/2018
07:14
hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/w063jpw First major milestone achieved now watch these rise....GLA
makeamillion1
24/9/2018
21:48
Fingers crossed.
paul_98
24/9/2018
21:33
paul. All I can say is that I hope you are right but I've been there, done that and I'm still waiting for that promised announcement two years after we were promised it. All we got was a totally revised development schedule instead of the promised announcement that the development was complete. As I said, I hope you are right and they keep their word this time.
daijavu
Chat Pages: 219  218  217  216  215  214  213  212  211  210  209  208  Older
ADVFN Advertorial
Your Recent History
LSE
AVO
Advanced O..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210614 09:47:37